Trial reportJapanese journal of clinical oncology2026
Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.
Trial report in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05101096 (A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is approved outside Japan for previously treated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) unresectable locally advanced or metastatic BC (mBC) based on the global, phase III TROPiCS-02 study. ASCENT-J02 (NCT05101096; jRCT2031210346), an open-label, phase I/II study, evaluated efficacy and safety of SG in Japanese participants with advanced solid tumors. We report phase II HR+/HER2- mBC cohort primary results.
methodsParticipants with previously treated HR+/HER2- mBC received SG 10 mg/kg intravenously on days 1 and 8, every 21 days until progression/unacceptable toxicity. Primary endpoint: confirmed independent review committee (IRC)-assessed objective response rate (ORR; Response Evaluation Criteria in Solid Tumors v1.1), with 10% threshold (H0: ORR ≤10% vs H1: ORR >10%; one-sided P < .025). Key secondary endpoints: investigator-assessed ORR, IRC and investigator-assessed progression-free survival (PFS), overall survival (OS), safety.
resultsForty-two participants received SG. At the 7.5-month median follow-up, ORR (95% CI) was 16.7% (7.0-31.4; P = .1214) by IRC and 28.6% (15.7-44.6) by investigator. Median PFS (95% CI) was 4.4 months (2.7-8.5) by IRC and 5.6 months (3.3-7.1) by investigator. Median OS (95% CI) was 13.0 months (11.0-not reached). Treatment-emergent adverse events (TEAEs) occurred in 41 (98%) participants (grade ≥ 3, 35 [83%]). No TEAE-related deaths reported; one participant discontinued treatment due to neutropenia.
conclusionsAlthough the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.